Overview

TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV

Status:
Completed

Trial end date:
2017-11-23

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to continue to provide Darunavir (DRV) to pediatric patients who previously received DRV in any of three pediatric clinical studies sponsored by Tibotec Pharmaceuticals and continue to benefit from using it, in countries where DRV is not yet commercially available for the pediatric patient, is not reimbursed or cannot be accessed through another source (like access program or government program).

Phase:

Phase 2

Details

Lead Sponsor:

Janssen Sciences Ireland UC

Treatments:

Darunavir
Pharmaceutical Solutions
Polystyrene sulfonic acid
Ritonavir